Start-up Meditope Biosciences Inc. tucked $3.6 million under its belt in a Series A funded by angel investors to advance its monoclonal antibody (MAb) linker technology. The Los Angeles-based biotech is advancing cancer therapeutics discovered at City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center in Duarte, Calif.